All In Biotech

Drug Trial Radar · NCT05458011

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study With an Open-Label Treatment Period of Fremanezumab Administered Subcutaneously Monthly or Quarterly for the Preventive Treatment of Migraine in Adult Chinese Patients

Last checked: Nov 20, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 365 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

365

Actual

Start

Sep 30, 2022

Primary completion

Jan 31, 2024

Study completion Jun 13, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine. Secondary Objectives: * To further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections. * To evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections.

Conditions

  • Migraine

Interventions

  • FremanezumabDrug

    Pharmaceutical form: solution for injection Route of administration: subcutaneous injection

  • PlaceboDrug

    Pharmaceutical form: solution for injection Route of administration: subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double Blind (DB) Period: Mean Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of FremanezumabTime frame: Baseline (Day -28 to Day -1), up to Week 12

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Teva Investigational Site 88028

    Baotou Shi, China

  • Teva Investigational Site 88004

    Beijing, China

  • Teva Investigational Site 88001

    Beijing, China

  • Teva Investigational Site 88008

    Changchun, China

  • Teva Investigational Site 88009

    Changchun, China

  • Teva Investigational Site 88022

    Changsha Shi, China

  • Teva Investigational Site 88030

    Changsha Shi, China

  • Teva Investigational Site 88003

    Chengdu, China

  • Teva Investigational Site 88029

    Chongqing, China

  • Teva Investigational Site 88019

    Fuzhou, China

  • Teva Investigational Site 88020

    Guangzhou, China

  • Teva Investigational Site 88013

    Guiyang, China

  • Teva Investigational Site 88026

    Harbin, China

  • Teva Investigational Site 88010

    Lianyungang, China

  • Teva Investigational Site 88005

    Luoyang, China

  • Teva Investigational Site 88033

    Rizhao, China

  • Teva Investigational Site 88021

    Shanghaishi, China

  • Teva Investigational Site 88025

    Shanghaishi, China

  • Teva Investigational Site 88016

    Shenyang, China

  • Teva Investigational Site 88011

    Shijiazhuang, China

  • Teva Investigational Site 88015

    Suzhou, China

  • Teva Investigational Site 88024

    Tianjin, China

  • Teva Investigational Site 88023

    Tianjin, China

  • Teva Investigational Site 88017

    Wenzhou, China

  • Teva Investigational Site 88012

    Wuhan, China

  • Teva Investigational Site 88006

    Wuhan, China

  • Teva Investigational Site 88032

    Xining, China

  • Teva Investigational Site 88031

    Zhanjiang, China

  • Teva Investigational Site 88034

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.